BioSyent (CVE:RX) Stock Price Passes Above 50-Day Moving Average – Here’s What Happened

Shares of BioSyent Inc. (CVE:RX) crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$14.23 and traded as high as C$14.75. BioSyent shares last traded at C$14.66, with a volume of 1,258 shares changing hands.

BioSyent Stock Performance

The company has a current ratio of 1.89, a quick ratio of 6.91 and a debt-to-equity ratio of 11.66. The firm’s fifty day moving average price is C$14.25 and its two-hundred day moving average price is C$14.42. The stock has a market capitalization of C$167.15 million, a PE ratio of 18.81 and a beta of 0.99.

Insider Transactions at BioSyent

In other news, Director Seyed Ahmad Ashrafi sold 1,884 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of C$14.65, for a total value of C$27,600.60. Following the transaction, the director owned 37,261 shares in the company, valued at C$545,873.65. This trade represents a 4.81% decrease in their ownership of the stock. In the last 90 days, insiders sold 4,358 shares of company stock valued at $63,132. Insiders own 33.65% of the company’s stock.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.